PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus
Abstract Background To assess the value of peptidoglycan recognition protein 2 (PGLYRP2) in assessing the disease activity and lipid metabolism in patients with systemic lupus erythematosus (SLE). Methods SLE patients with stable disease (n = 15), active lupus nephritis (LN) (n = 15) and neuropsychi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-08-01
|
| Series: | Lipids in Health and Disease |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12944-021-01515-8 |
| _version_ | 1819116325055758336 |
|---|---|
| author | Hui Li Defang Meng Jieting Jia Hua Wei |
| author_facet | Hui Li Defang Meng Jieting Jia Hua Wei |
| author_sort | Hui Li |
| collection | DOAJ |
| description | Abstract Background To assess the value of peptidoglycan recognition protein 2 (PGLYRP2) in assessing the disease activity and lipid metabolism in patients with systemic lupus erythematosus (SLE). Methods SLE patients with stable disease (n = 15), active lupus nephritis (LN) (n = 15) and neuropsychiatric systemic lupus erythematosus (NP-SLE) (n = 15) admitted to Northern Jiangsu People’s Hospital (Jiangsu, China) in 2019–2020 were recruited. In addition, volunteers with matched age and sex (n = 15) were enrolled as controls. The level of PGLYRP2 in the serum and its expression in peripheral blood mononuclear cells (PBMCs) were measured. The link between PGLYRP2 level and clinical parameters (including lipid profile) was described. Results Serum PGLYRP2 level in SLE cases exceeded that in healthy volunteers (3938.56 ± 576.07 pg/mL), and significantly higher in active LN (5152.93 ± 446.13 pg/mL) and NP-SLE patients (5141.52 ± 579.61 pg/mL). As shown by quantitative real-time PCR results, the expression of PGLYRP2 in PBMCs of SLE patients with active LN and NP-SLE surpassed that in healthy volunteers (P < 0.01). Receiver operating characteristic (ROC) curves demonstrated that PGLYRP2 was capable of distinguishing stable SLE from active LN (AUC = 0.841, 95%CI = 0.722–0.960, P = 0.000). PGLYRP2 level positively correlated with SLEDAI of SLE patients (r = 0.5783, P < 0.01). Moreover, its level varied with serological and renal function parameters (complement 3, complement 4, estimated glomerular filtration rate and 24-h urine protein) and immunoglobulin A (IgA) of SLE. A potential correlation between PGLYRP2 level and lipid profile (HLD-c, Apo-A1 and Apo B/A1) was determined in SLE patients. The linear regression analysis indicated SLEDAI as an independent factor of PGLYRP2 level, with a positive correlation in between (P < 0.05). Conclusions Serum PGLYRP2 level significantly increases in SLE patients, and is positively correlated to SLEDAI. Moreover, serum PGLYRP2 level is correlated with renal damage parameters and the abnormal lipid profile of SLE. PGLYRP2 could be used to predict SLE activity, dyslipidemia and cardiovascular disease risks in SLE patients. |
| first_indexed | 2024-12-22T05:15:17Z |
| format | Article |
| id | doaj.art-18a4702361e94f5497163d0a87b35c42 |
| institution | Directory Open Access Journal |
| issn | 1476-511X |
| language | English |
| last_indexed | 2024-12-22T05:15:17Z |
| publishDate | 2021-08-01 |
| publisher | BMC |
| record_format | Article |
| series | Lipids in Health and Disease |
| spelling | doaj.art-18a4702361e94f5497163d0a87b35c422022-12-21T18:37:53ZengBMCLipids in Health and Disease1476-511X2021-08-012011910.1186/s12944-021-01515-8PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosusHui Li0Defang Meng1Jieting Jia2Hua Wei3Northern Jiangsu People’s Hospital, Affiliated Hospital to Yangzhou UniversityNorthern Jiangsu People’s Hospital, Affiliated Hospital to Yangzhou UniversityNorthern Jiangsu People’s Hospital, Affiliated Hospital to Yangzhou UniversityNorthern Jiangsu People’s Hospital, Affiliated Hospital to Yangzhou UniversityAbstract Background To assess the value of peptidoglycan recognition protein 2 (PGLYRP2) in assessing the disease activity and lipid metabolism in patients with systemic lupus erythematosus (SLE). Methods SLE patients with stable disease (n = 15), active lupus nephritis (LN) (n = 15) and neuropsychiatric systemic lupus erythematosus (NP-SLE) (n = 15) admitted to Northern Jiangsu People’s Hospital (Jiangsu, China) in 2019–2020 were recruited. In addition, volunteers with matched age and sex (n = 15) were enrolled as controls. The level of PGLYRP2 in the serum and its expression in peripheral blood mononuclear cells (PBMCs) were measured. The link between PGLYRP2 level and clinical parameters (including lipid profile) was described. Results Serum PGLYRP2 level in SLE cases exceeded that in healthy volunteers (3938.56 ± 576.07 pg/mL), and significantly higher in active LN (5152.93 ± 446.13 pg/mL) and NP-SLE patients (5141.52 ± 579.61 pg/mL). As shown by quantitative real-time PCR results, the expression of PGLYRP2 in PBMCs of SLE patients with active LN and NP-SLE surpassed that in healthy volunteers (P < 0.01). Receiver operating characteristic (ROC) curves demonstrated that PGLYRP2 was capable of distinguishing stable SLE from active LN (AUC = 0.841, 95%CI = 0.722–0.960, P = 0.000). PGLYRP2 level positively correlated with SLEDAI of SLE patients (r = 0.5783, P < 0.01). Moreover, its level varied with serological and renal function parameters (complement 3, complement 4, estimated glomerular filtration rate and 24-h urine protein) and immunoglobulin A (IgA) of SLE. A potential correlation between PGLYRP2 level and lipid profile (HLD-c, Apo-A1 and Apo B/A1) was determined in SLE patients. The linear regression analysis indicated SLEDAI as an independent factor of PGLYRP2 level, with a positive correlation in between (P < 0.05). Conclusions Serum PGLYRP2 level significantly increases in SLE patients, and is positively correlated to SLEDAI. Moreover, serum PGLYRP2 level is correlated with renal damage parameters and the abnormal lipid profile of SLE. PGLYRP2 could be used to predict SLE activity, dyslipidemia and cardiovascular disease risks in SLE patients.https://doi.org/10.1186/s12944-021-01515-8Systemic lupus erythematosusSLE disease activity indexPGLYRP2Lipid profile |
| spellingShingle | Hui Li Defang Meng Jieting Jia Hua Wei PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus Lipids in Health and Disease Systemic lupus erythematosus SLE disease activity index PGLYRP2 Lipid profile |
| title | PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus |
| title_full | PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus |
| title_fullStr | PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus |
| title_full_unstemmed | PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus |
| title_short | PGLYRP2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus |
| title_sort | pglyrp2 as a novel biomarker for the activity and lipid metabolism of systemic lupus erythematosus |
| topic | Systemic lupus erythematosus SLE disease activity index PGLYRP2 Lipid profile |
| url | https://doi.org/10.1186/s12944-021-01515-8 |
| work_keys_str_mv | AT huili pglyrp2asanovelbiomarkerfortheactivityandlipidmetabolismofsystemiclupuserythematosus AT defangmeng pglyrp2asanovelbiomarkerfortheactivityandlipidmetabolismofsystemiclupuserythematosus AT jietingjia pglyrp2asanovelbiomarkerfortheactivityandlipidmetabolismofsystemiclupuserythematosus AT huawei pglyrp2asanovelbiomarkerfortheactivityandlipidmetabolismofsystemiclupuserythematosus |